Taylor Wessing LLP advises Oxford BioMedica on a new collaboration with Sanofi-Aventis
Leading law firm Taylor Wessing LLP has advised Oxford BioMedica (LSE: OXB) on the negotiation of a new collaboration to develop novel gene-based medicines for the treatment of ocular diseases.
Oxford BioMedica, a long standing client of Taylor Wessing, is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The company will receive an upfront payment of US$26 million (£18 million) and committed funding of up to a further US$24 million (£16 million) over three years. In addition, Sanofi-Aventis has an exclusive option for a worldwide licence to develop and commercialise four ocular products. If successful, Oxford BioMedica will receive further undisclosed licence fees, milestone payments and royalties on product sales, the terms of which are consistent with other deals of this size and scope.
Malcolm Bates, partner and Head of Taylor Wessing's Life Science and Healthcare Group, comments:
“It is has been very satisfying to assist Oxford BioMedica on a deal which enables further products based on the company’s founding LentiVector® technology to move into the clinical phase of development in partnership with Sanofi-Aventis.”
Taylor Wessing LLP has a long-established reputation as a leader in the life sciences space. The firm was named European Life Sciences Firm of the Year at the 2008 Managing IP Global Awards; and won UK Contentious IP Firm of the Year at the 2009 Managing IP Global Awards.
The Taylor Wessing team advising Oxford Biomedica was led by partner Malcolm Bates, and included Tim Worden and Loretta Pugh.
Ends
Notes to editors
For more information or to speak to Malcolm Bates please contact Sarah le Cheminant at Taylor Wessing:
Tel: +44 (0)20 7300 4930
Email: s.lecheminant@taylorwessing.com
Taylor Wessing LLP: Life Sciences & Healthcare
Life sciences and healthcare is one of the world's fast-growing markets. Biotech development and genetic engineering are powerful drivers in this dynamic field, promoting the development of innovative products in both the pharmaceutical and food industries. In turn, legislators are responding with new laws and guidelines with which to regulate the sector.
In this environment, Taylor Wessing's life sciences and healthcare group has built on its market-leading reputation in IP services for pharmaceutical, medical device and biotech clients to create an integrated team of specialists able to meet the diverse needs of the full range of organisations working in this sector.
Taylor Wessing LLP is a leading law firm providing legal support for commercial organisations doing business in Europe, the Middle East and China.
www.taylorwessing.com
Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include GlaxoSmithKline, Merck & Co, Open Biosystems and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.
